GLENMARK PHARMACEUTICALS INC., USA

Glenmark to Launch Generic Ropivacaine Anesthesia Drug in US Market

- Glenmark Pharmaceuticals' US subsidiary will launch generic Ropivacaine Hydrochloride injection in November 2025, offering a bioequivalent alternative to Fresenius Kabi's Naropin. - The long-acting anesthetic drug is indicated for producing local or regional anesthesia in surgical procedures for adults, with the reference product generating $20.9 million in sales over the past twelve months. - The generic version will be available in three single-dose vial strengths (40 mg/20 ml, 150 mg/30 ml, and 200 mg/20 ml), expanding Glenmark's injectable portfolio. - This launch reinforces Glenmark's commitment to providing quality and affordable medical alternatives to patients in need across the US market.